iLet ‘bionic’ pancreas trial

Beta Bionics, based in the US, has announced the first patients have begun home use of dasiglucagon – a stable glucagon analogue – in a clinical trial of the company’s iLet bionic pancreas system for people with Type 1 diabetes.

The iLet device features an autonomous, dual-chamber infusion pump that is powered by dosing algorithms. Using machine learning and data from a continuous glucose monitor, the algorithms calculate and dose insulin and/or glucagon as needed. The iLet can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas (insulin and glucagon), and the trial will compare the operational performance in its insulin-only configuration to that of its bihormonal configuration using dasiglucagon.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags